NCT02659020: A reported trial by Eli Lilly and Company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02659020 |
|---|---|
| Title | A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 1, 2016 |
| Completion date | July 28, 2020 |
| Required reporting date | July 28, 2021, midnight |
| Actual reporting date | July 26, 2021 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |